Approved for use through 09/30/00. OMB 0651\_0032/

Under th	e Pagerwor)	Reduction	Act of 19	95, no persons are required to	respond to	Patent a a collection	ind Trad	emark O: ation unles	ffice: U.S. DEPARTMENT OF s it displays a valid OMB control numb	COMMERCE
41	CZ/								te if Known	7
1	37					ation Nu	mber		10/811,260	7
	(F) 1001	FEE T	RANSM	ITTAL	Filing	Date			March 26, 2004	_
17 14	O)				First P	Named In	ventor		Arbuthnot	
1				ber 10, 1998.		Art Unit			1625	
				o annual revision.	Examine				C. Chang	
ENTAN		OF PAYM		(\$)180.00	Attorne	y Docke			X10443F	
	METHO	D OF P.	AYMENT	(check one)	2 2=				ATION (continued)	
1.		The Commis	ssioner is	hereby authorized to	3. AI Large	DITION: Entit	Small	Entity		
	IXI		dicated fo	es and credit any	Fee	y Fee	Fee	Fee	Fee Description	Fee
Den	osit				Code 105	(\$) 130	Code 205	(\$) 65	Surcharge-late filing fee or	Paid
Acc	ount	05-08	340		103	130	203	03	oath,	
	osit	Eli I	iilly	and Company	127	50	227	25	Surcharge-late provisional	
Acc	ount Name			and company				•	filing fee or cover sheet.	
Х	Requir 37 CFR	Any onal Fee ed Under 1.16 and		Charge the Issue Fee Set in 37 CFR 1.18 at the Mailing of the Notice of Allowance	139	130	139	130	Non-English specification .	
2.	1.17	Payment En	closed:		147	2,520	147	2,520	For filing a request for -	
1	ш								reexamination	·
	ſ	Che	eck	Money Other	112	920*	112	920*	Requesting publication of SIR	
	Ŀ		L	Order	113	1,840	113	1,840*	prior to Examiner action Requesting publication of SIR	$\vdash$
						•	·		after Examiner action	
		FEE C	ALCUL	TION	115	110	215	55	Extension for reply within first month	L
					116	430	216	215	Extension for reply within second month	
1.	FILI	NG FEE			117	980	217	490	Extension for reply within third month	
Large	Entity	Small	Entity		118	1,530	218	765	Extension for reply within	$\vdash$
Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Fee Description Paid					fourth month	
101	790	201	395	Utility filing fee	128	2,080	228	1,040	Extension for reply within fifth month	
106	350	206	175	Design	119	340	219	170	Notice of Appeal	
107	550	207	275	filing fee Plant filing fee	120	340	220	170	Filing a brief in support of an appeal	
108	790	208	395	Reissue	121	300	221	150	Request for oral hearing	
114	160	214	80	filing fee Provisional	138	1,510	138	1,510	Petition to institute a public	
				filing fee	140	110	240	55	use proceeding Petition to revive-unavoidable	
	S	UBTOTAL	(1) (	\$)0.00	141	1,370	241	685	Petition to revive-	
					142	1,370	242	685	unintentional Utility issue fee (or reissue)	<del></del>
2.	CLAI	MS	Extr	Fee from Fee Paid below	143	490	243	245	Design Issue Fee	
Total		-20**=		x 18 =	144	660	244	330	Plant Issue Fee	
Claims Independ	dent -	-3**=	H	x 88 =	122	130	122	130	Petitions to the Commissioner	$\vdash$
Claims Multiple	e Dependen	J	$\vdash$	300 =	123	50	123	50	Petitions related to	$\vdash$
	st time)		لـــا						provisional applications	100
					126	180	126	180	Submission of Information Disclosure Stmt.	180
1					581	40	581	40	Recording each patent assignment per property (times	
Large	Entity	Small	Entity	Fee Description	146	790	246	395	number of properties) Filing a submission after final	<u> </u>
Fee Code	Fee (\$)	Fee Code	Fee (\$)				240	555	rejection (37 CFR 1.129(a))	
103	18	203	9	Claims in excess of 20	149	790	249	395	For each additional invention to be examined (37 CFR 1.129(b))	
102	88	202	44	Independent claims in	179	790	279	395	Request for Continued	$\vdash$
104	300	204	150	excess of 3 Multiple dependent	169	900	169	900	Examination (RCE) Request for expedited	<del>                                     </del>
				claim					examination of a design application	
109	88	209	44	Reissue independent	Other fe	ee (speci	fy) <u>Ter</u>	minal Disc	claimer 1.321	
<b></b>			_	claims over original patent						
110	18	210	9	Reissue claims in excess of 20 and over	Other fe	ee (speci	fy)			
**or	number pro	SUBTOTA eviously p		original patent (\$)0.00	*Reduced	by Basic F	iling Fee	Paid	SUBTOTAL (3) (\$)180.0	00
greate	r; For Re	issues, se			L					
Typed I	TED BY	Gilbert	T Vov						Complete (if applicable)	
Signati		Dep	·· voy	750/					Reg. Number 43,972 Date October 6, 2004	
<del></del>	1	_/<-		CERT	IFICATI	OF MA	ILING			
I here	eby cert	ify tha	t this	correspondence is be	ing depo	sited w	ith Unit	ed Stat	es Postal Service as first	class
								450, Al	exandria, VA 22313-1450, o	on the
aate a	uppearir	ng below	527	Koades EL	I LILLY	AND COM	PANY /	1-12-1	) <del>Y</del>	
			Ву					D	ate	

OCT 1 4 2004 SE

## CERTIFICATE OF MAILING

. (

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

By KSRhoades ELI LILLY AND COMPANY
Date 10-12-04

## PATENT APPLICATION IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Arbuthnot, et al.	) .	120
Serial Number	:	10/811,260	) )	4
Filed:	:	March 26, 2004	) ). )	Group Art Unit
For	:	BENZOTHIOPHENES, FORMULATIONS CONTAINING SAME, AND METHODS	) ) )	Examiner:
Docket No.	:	X-10443F	) )	C. Chang

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure in accordance with 37 C.F.R. §1.56, Applicant wishes to bring to the attention of the Examiner the patents, publications and/or other information listed on the attached PTO Form 1449 (modified). Copies of cited items are enclosed in accordance with 37 C.F.R. § 1.98. Applicants note that the two applications in the chain of priority for the present application have matured into U.S. patents (U.S. Patent No.'s 6,458,811 and 6,797,719) that are the subject of pending district court litigation. The filing of this Information Disclosure Statement shall not be construed as an admission that the information cited is, or is considered to be, material to patentability as defined in § 1.56(b).

10/15/2004\_JADD01 00000001 050840 10811260

01 FC:1806

180.00 DA

Since this Statement is being filed after the period specified in §1.97(b), but before the mailing date of a final action or a notice of allowance, please charge the amount of \$180.00, the fee under 37 C.F.R. 1.17(p), and charge any additional fees which may be required by this or any other related paper, or credit any overpayment to Deposit Account No. 05-0840.

Applicants request consideration of this information.

Respectfully submitted,

Gilbert T. Voy

Attorney for Applicant Registration No. 43,972

Phone: 317-276-2966

Eli Lilly and Company Patent Division/GTV Lilly Corporate Center Indianapolis, Indiana 46285

October 6,200m

FORM (modified)

Atty. Docket No. X10443F

INFORMATION DISCLOSURE CITATION Applicants
IN AN APPLICATION

Arbuthnot, et al.

Filing Date March 26, 2004 Group 1625

Examiner	Cite No. 1	Foreign Patent Document	•	Name of Patentee or		T <sup>6</sup>
Initials*		Country Code <sup>3</sup> -Number <sup>4-</sup> Kind Code5 (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	BG	CA 2,158,399				
	ВН	GB 2,097,788				· V
	BC					
	BD					
	BE		M. P. M.			
	BF					
	BG					
	ВН					
	BI					
	BJ					
,	BK		·····			
<del></del> .	BL					
	BM					
	BN		•			
<del>.</del>	ВО		· · · · · · · · · · · · · · · · · · ·			
			<b></b>			
	BP					
•	BQ					
	BR					

OIPE	VC13
OCT 1	7 5004 P. S.
ODINDERAL	1400 difie

_ \s. wi			Sheet 2 of 2		
FORM (44.90 modified)	Atty. Docket No. X10443F	Serial No 10/811,260			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicants Arbuthnot, et al.				
	Filing Date March 26, 2004	Group 1625			

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	<sub>T</sub> 6
Initials*	No. 1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	1
	CG	Pharmaceutics: The Science of Dosage Form Design, Churchill Livingston, New York, NY, Chapters 1 and 13, (1988).	
	СН	Remington's Pharmaceutical Sciences, 18 <sup>th</sup> Ed., Mack Publishing Company, Eaton, PA, Chapters 19, 31 and 89, (1990).	
	CI	Barr Laboratories, Inc. October 1, 2004 Paragraph IV Certification Letter to Eli Lilly & Company Re: U.S. Patent No. 6,797,719	
	CD		
-	CE		
•	CF		
	CG		
	СН		
	CI		
	CJ		÷
	СК		
	CL		- ""
	СМ	·	
	CN		<u> </u>
kaminer	<del>                                     </del>	Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.